Romano Francesco Jacopo, Rossetti Sabrina, Conteduca Vincenza, Schepisi Giuseppe, Cavaliere Carla, Di Franco Rossella, La Mantia Elvira, Castaldo Luigi, Nocerino Flavia, Ametrano Gianluca, Cappuccio Francesca, Malzone Gabriella, Montanari Micaela, Vanacore Daniela, Quagliariello Vincenzo, Piscitelli Raffaele, Pepe Maria Filomena, Berretta Massimiliano, D'Aniello Carmine, Perdonà Sisto, Muto Paolo, Botti Gerardo, Ciliberto Gennaro, Veneziani Bianca Maria, De Falco Francesco, Maiolino Piera, Caraglia Michele, Montella Maurizio, De Giorgi Ugo, Facchini Gaetano
Progetto ONCONET2.0, Linea Progettuale 14 per L'implementazione della Prevenzione e Diagnosi Precoce del Tumore alla Prostata e Testicolo, Regione Campania, Italy.
Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori 'Fondazione G. Pascale', IRCCS, Naples, Italy.
Oncotarget. 2016 Dec 20;7(51):85641-85649. doi: 10.18632/oncotarget.13063.
Notwithstanding the peculiar sensitivity to cisplatin-based treatment, resulting in a very high percentage of cures even in advanced stages of the disease, still we do not know the biological mechanisms that make Testicular Germ Cell Tumor (TGCT) "unique" in the oncology scene. p53 and MDM2 seem to play a pivotal role, according to several in vitro observations, but no correlation has been found between their mutational or expression status in tissue samples and patients clinical outcome. Furthermore, other players seem to be on stage: DNA Damage Repair Machinery (DDR) , especially Homologous Recombination (HR) proteins, above all Ataxia Telangiectasia Mutated (ATM), cooperates with p53 in response to DNA damage, activating apoptotic cascade and contributing to cell "fate". Homologous Recombination deficiency has been assumed to be a Germ Cell Tumor characteristic underlying platinum-sensitivity, whereby Poly(ADP-ribose) polymerase (PARP), an enzyme involved in HR DNA repair, is an intriguing target: PARP inhibitors have already entered in clinical practice of other malignancies and trials are recruiting TGCT patients in order to validate their role in this disease. This paper aims to summarize evidence, trying to outline an overview of DDR implications not only in TGCT curability, but also in resistance to chemotherapy.
尽管对基于顺铂的治疗具有特殊敏感性,即使在疾病晚期也能实现很高的治愈率,但我们仍不清楚使睾丸生殖细胞肿瘤(TGCT)在肿瘤学领域“独特”的生物学机制。根据多项体外观察结果,p53和MDM2似乎起着关键作用,但在组织样本中它们的突变或表达状态与患者临床结局之间未发现相关性。此外,其他因素似乎也在发挥作用:DNA损伤修复机制(DDR),尤其是同源重组(HR)蛋白,最重要的是共济失调毛细血管扩张突变蛋白(ATM),在DNA损伤反应中与p53协同作用,激活凋亡级联反应并决定细胞“命运”。同源重组缺陷被认为是生殖细胞肿瘤对铂类药物敏感的一个特征,因此,参与HR DNA修复的酶聚(ADP-核糖)聚合酶(PARP)成为一个引人关注的靶点:PARP抑制剂已应用于其他恶性肿瘤的临床治疗,并且正在招募TGCT患者进行试验,以验证其在该疾病中的作用。本文旨在总结相关证据,试图概述DDR不仅在TGCT治愈率方面,而且在化疗耐药性方面的影响。